Seeking Alpha

Alexion Pharmaceuticals (ALXN) agrees to buy privately-held biotech firm Enobia for $1.08B in...

Alexion Pharmaceuticals (ALXN) agrees to buy privately-held biotech firm Enobia for $1.08B in cash - with $610M paid up front and the rest after various regulatory and sales milestones are hit. Enobia is focused on therapies treating patients with ultra-rare, life-threatening genetic disorders. Shares -1.3% AH. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs